38.86
-1.40 (-3.48%)
| Previous Close | 40.26 |
| Open | 39.22 |
| Volume | 733,263 |
| Avg. Volume (3M) | 1,135,667 |
| Market Cap | 2,772,881,152 |
| Price / Book | 4.78 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Diluted EPS (TTM) | -3.00 |
| Total Debt/Equity (MRQ) | 10.18% |
| Current Ratio (MRQ) | 27.68 |
| Operating Cash Flow (TTM) | -155.26 M |
| Levered Free Cash Flow (TTM) | -97.14 M |
| Return on Assets (TTM) | -23.46% |
| Return on Equity (TTM) | -39.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Vera Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | 3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 1.60 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.97% |
| % Held by Institutions | 112.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sofinnova Investments, Inc. | 31 Dec 2025 | 2,793,987 |
| Integral Health Asset Management, Llc | 31 Dec 2025 | 1,800,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (HC Wainwright & Co., 183.07%) | Buy |
| Median | 99.00 (154.76%) | |
| Low | 88.00 (Wolfe Research, 126.45%) | Buy |
| Average | 99.00 (154.76%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 41.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wolfe Research | 11 Mar 2026 | 88.00 (126.45%) | Buy | 42.04 |
| HC Wainwright & Co. | 02 Mar 2026 | 110.00 (183.07%) | Buy | 40.42 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| WRIGHT-MITCHELL JANE | 40.73 | - | 42,403 | 1,727,074 |
| Aggregate Net Quantity | 42,403 | |||
| Aggregate Net Value ($) | 1,727,074 | |||
| Aggregate Avg. Buy ($) | 40.73 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WRIGHT-MITCHELL JANE | Officer | 23 Mar 2026 | Acquired (+) | 42,403 | 40.73 | 1,727,074 |
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 28 Jan 2026 | Announcement | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer |
| 09 Jan 2026 | Announcement | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 08 Jan 2026 | Announcement | Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 07 Jan 2026 | Announcement | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |